“What’s New Doc?” in GI Cancer

Join us for insightful updates on the forefront of gastrointestinal (GI) cancer research with our new series, “What’s New Doc?” in GI Cancer. Each week, experts in the field will share comprehensive information and provide fresh perspectives on the latest data, offering valuable insights into GI cancer treatment and research.

Explore a diverse range of cutting-edge communication as we bring you the most recent advancements in GI cancer research. Stay tuned for weekly updates that promise to enhance your understanding of the evolving landscape in GI cancer treatment.

Episode 7: The KEYNOTE 811 trial

In the KEYNOTE 811 study, a randomised, double-blind phase 3 trial, the combination of trastuzumab plus pembrolizumab was investigated in patients with HER2-positive metastatic gastroesophageal junction or gastric cancer in the first-line treatment. The trial included patients treated with chemotherapy

See video »

Z1. Researchpark 30, 1731 Zellik, Belgium
Website created by MediMix © 2023 - Privacy Policy